Mobius Therapeutics(TM) Receives Payment Indicator for Reimbursement of Mitosol(R)

Reimbursement to Compounded Medication Excluded Under This Code

(firmenpresse) - ST. LOUIS, MO -- (Marketwire) -- 03/11/13 -- Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company, has received notice from the Center for Medicare Services (CMS) of an Outpatient Prospective Payment System (OPPS) Payment Indicator "K2" for the code J7315 reimbursing Mitosol® (mitomycin for solution) Kit for Ophthalmic Use. This payment indicator allows payment for entities billing under OPPS, including Ambulatory Surgical Centers (ASCs) and hospitals.

"This is a substantial milestone and confirms the inherent value represented by Mitosol®," said Ed Timm, President of Mobius Therapeutics. "In light of the ongoing concerns related to the sterility and quality assurance of compounded medications, this will give providers and patients peace of mind, knowing that the precision, safety, and convenience of Mitosol® is also the wise economic choice."

J-codes are part of the Health Common Procedure Coding System (HCPCS) and are used by providers to identify drugs and facilitate their reimbursement. These codes are acknowledged by Medicare and most private insurance carriers.

"This further validates the inherent value of FDA approved formulations versus compounded medications," continued Timm. "In the end, everyone wins: the patient, the provider, and the American healthcare system."

Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.

Image Available:



:
Jim Anderson
Mobius Therapeutics, LLC
314-615-6930


Andy Likes
The Vandiver Group, Inc.
314-991-4641

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 11.03.2013 - 11:00 Uhr
Sprache: Deutsch
News-ID 237856
Anzahl Zeichen: 0

contact information:
Town:

ST. LOUIS, MO

Kategorie:

Hospitals, Facilities and Providers

Diese Pressemitteilung wurde bisher 214 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Mobius Therapeutics(TM) Receives Payment Indicator for Reimbursement of Mitosol(R)"
steht unter der journalistisch-redaktionellen Verantwortung von

Mobius Therapeutics, LLC (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Mobius Therapeutics(TM) Provides Update on Recall of Two Lots of Mitosol(R) ...

ST. LOUIS, MO -- (Marketwire) -- 02/20/13 -- Mobius Therapeutics, the makers of , announced today that the source for the recent voluntary recall of two lots was likely due to laboratory contamination induced at the time of testing."Upon invest ...

Mobius Therapeutics, LLC Issues a Voluntary Recall of Mitosol(R) (mitomycin for ...

ST. LOUIS, MO -- (Marketwire) -- 01/10/13 -- On 10 January 2013, Mobius Therapeutics, LLC, St. Louis, MO, announced today that it is conducting a voluntary recall of 2 lots of Mitosol® (mitomycin for solution), 0.2 mg/vial, Kit for Ophthalmic Use. ...

Alle Meldungen von Mobius Therapeutics, LLC